Tag: drug-coated balloons

Paclitaxel mortality signal inconsistent across different geographies

While drug-coated balloons (DCBs) have been “consistently efficacious” across various studies, the mortality signal has not, Peter Schneider (University of California San Francisco, San...
panos kitrou discusses drug-coated balloons central venous stenosis

Analysis of DCB use for treatment of central venous stenosis shows...

According to the findings of a European multicentre retrospective analysis, the use of drug-coated balloons (DCBs) for the treatment of symptomatic central venous stenosis...

VIVA 2019: SELUTION sirolimus DCB safe and effective through two years

The SELUTION SFA trial met its primary endpoint and demonstrated an late lumen loss of 0.19mm. Furthermore, excellent freedom from clinically driven TLR was...

Philips receives FDA approval for low-dose drug-coated balloons

Philips has received US Food and Drug Administration (FDA) approval for two Stellarex 0.035” low-dose (200mm and 150mm) drug-coated balloons for the treatment of...

A panel of experts comments on IN.PACT AV ACCESS data

NOTE: This video is ONLY available to watch in selected countries and geographies   Jos van den Berg (Lugano, Switzerland) speaks to Andrew Holden (Auckland, New...
MDA

MHRA issues medical device alert for paclitaxel use in the UK

Do not use paclitaxel drug-coated balloons (DCBs) or drug-eluting stents (DESs) in the routine treatment of patients with intermittent claudication until further notice, a...
paclitaxel

Meta-analysis finds a higher risk of death in the long term...

New data, just published in the Journal of the American Heart Association (JAHA), suggest that there is an increased risk of death at two...
paclitaxel

Without additional long-term and patient-level data, Katsanos et al’s conclusion is...

By Thomas Zeller The Katsanos et al meta-analysis reports an increased risk of mortality beyond one year across randomised studies of paclitaxel-coated balloons (DCB) and...

Two-year ILLUMENATE Global data find 72.4% primary patency with Stellarex DCB

After two years of follow-up, the ILLUMENATE Global study has confirmed the durability of the Stellarex drug-coated balloon (Spectranetics/Philips) with primary patency rates comparable...

Particulate embolisation after femoral artery treatment with drug-coated balloons

Drug-eluting technologies, such as balloons coated with paclitaxel (DCB), are now the gold standard treatment for patients presenting with symptomatic peripheral artery disease (PAD) in the...

Global cohorts report drug-coated balloon success above the knee and “promising”...

Three global registries reported fresh data at the 2017 Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany), all of which showed encouraging outcomes for...

Medtronic announces Health Canada licence for IN.PACT Admiral drug-coated balloon

Medtronic Canada, a subsidiary of Medtronic, has announced it has obtained Health Canada licence for the IN.PACT Admiral drug-coated balloon. IN.PACT Admiral is a primary...

Initial patients enrolled in first-in-man study of Selution sirolimus-coated balloon

Med Alliance has announced first patient enrolment in the first-in-man study of the Selution novel sirolimus-coated balloon. Patients were enrolled at the Universitaets-Herzzentrum, Bad...